
Coca-Cola Europacific Partners PLC (CCEP) Q2 2026 Earnings Call Transcript
Coca-Cola Europacific Partners PLC (CCEP) Q2 2026 Earnings Call Transcript
تابع أحدث الأخبار المالية والاقتصادية وتحديثات الأسواق والتقارير والتحليلات على PipVero.

Coca-Cola Europacific Partners PLC (CCEP) Q2 2026 Earnings Call Transcript

PENN's Q2 results are likely to reflect stable retail gaming demand and Interactive momentum, offset by Aurora closure and macro pressures.

CNO posts a Q2 earnings beat as higher collected premiums and net investment income lift results, prompting the company to raise its 2026 EPS outlook.

With CAPEX expanding, enterprise backlogs swelling, and the juiciest margins in history, the AI bullish narrative remains intact.

AVO's Calavo deal adds packing capacity, prepared foods and $25M in synergies, opening new paths for profitable long-term growth.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hub Group To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Hub Group between April 28, 2023 and May 11, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - August 4, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hub Group, Inc. ("Hub Group" or the "Company") (NASDAQ: HUBG) and reminds investors of the August 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Intuit To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Intuit between August 22, 2025 and May 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - August 4, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Intuit Inc. ("Intuit" or the "Company") (NASDAQ: INTU) and reminds investors of the September 8, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Erasca To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Erasca between January 14, 2025 and April 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - August 4, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

AI server names are ripping higher Tuesday afternoon as a broad risk-on wave sweeps through technology.

Reliance (RS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

BJ's Restaurants (BJRI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

MED tops Q2 earnings expectations despite lower sales, as rising coach productivity helps offset pressure from a shrinking coach network.

Cactus, Inc. (WHD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.

APO's Q2 results are affected by higher expenses as adjusted net income misses estimates. Higher AUM and revenue growth provide support.